Research shows that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) positively impact kidney transplant patients with type 2 diabetes.
Such patients face immense health risks, such as higher vulnerability to heart diseases and transplant failure. Moreover, it is harder for them to manage diabetes due to drug interactions and the likelihood of organ rejection.
GLP-1 RAs help regulate blood sugar levels and provide several cardiovascular and renal benefits. For instance, they simultaneously trigger the release of insulin and the lowering of glucagon levels, thereby enhancing overall glucose management.
Although they’ve been traditionally used to treat type 2 diabetes, they’re now proving useful in treating kidney transplant patients.
Benefits for Kidney Transplant Patients
Recent studies highlight the potential of GLP-1 RAs in post-transplant diabetes management. One study by researchers at NYU Langone Health showed a 31 percent reduction in all-cause mortality among kidney transplant recipients. The patients were also 49 percent less likely to experience organ failure.
These findings suggest a promising shift in diabetes treatment strategies for these patients.
How GLP-1 RAs Work
Apart from blood sugar control, GLP-1 RAs also provide many other benefits. In particular, they reduce the risk of major cardiovascular events and may have a protective effect on the kidneys. Consequently, they lower the risk of complications associated with type 2 diabetes.
Additionally, these drugs slow gastric emptying, which helps with appetite control and weight loss. This mechanism is particularly beneficial for transplant recipients, as obesity increases the risk of graft failure.
Incorporating GLP-1 RAs into post-transplant care could revolutionize treatment for diabetic kidney recipients. Physicians may now consider these drugs to prevent cardiovascular and renal complications.
Risks on Kidney Transplant Patients
While GLP-1 RAs offer multiple benefits, they come with potential side effects. Common issues include nausea, vomiting, and diarrhea. Fortunately, most of these side effects diminish over time.
There are other more serious potential side effects, though, such as inflammation in the pancreas, liver issues, or thyroid cancer. While the patients in the study didn’t suffer these, they had a 49 percent higher chance of developing diabetic retinopathy. This condition is potentially blinding and often comes with diabetes with uncontrolled blood sugar levels.
Hence, researchers emphasize the need for long-term studies. The impact of GLP-1 RAs on transplant rejection and kidney function requires further investigation. Still, current data supports their use in the study’s patient group.
Researcher’s Recommendations
“Our study results are the strongest evidence to date that GLP-1 agonist drugs are largely safe and effective tools for addressing type 2 diabetes in kidney transplant recipients,” remarked study lead investigator, obesity medicine specialist, and transplant surgeon Babak Orandi, MD, PhD.
“Our findings also show that while the benefits of GLP-1 drugs are significant, their use does come with some added risk of diabetic retinopathy, suggesting that physicians need to carefully monitor the eye health of kidney transplant recipients with diabetes who are started on these drugs,” noted Mara McAdams-DeMarco, PhD. McAdams-Demarco.
Demarco is the study’s senior investigator and epidemiologist. In addition, she is an associate professor in the Departments of Surgery and Population Health at NYU Grossman School of Medicine.
Image by gpointstudio on Freepik
